On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc ...

Regeneron reported that, on a combined basis, Eylea 2 mg and Eylea HD maintained their leadership position in the anti-VEGF category leader in 2024 in the United States. On a preliminary basis ...

Department of Integrative Physiology, University of Colorado Boulder (S.D., K.O.M., K.R.L., K.H.A., D.H.C., K.A.F., D.R.S., M.J.R.). Department of Integrative ...

April 5, 2021, Paper: "This paper documents the existence of a “middle-income trap” for the Middle East and North Africa region and contrasts the evidence with that of the East Asia and Pacific region ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

San Francisco, California--(Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

SAN FRANCISCO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024 ...